SIRP-EV

SIRP-EV is a therapeutic platform consisting of mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) engineered to express a high-affinity variant of the signal regulatory protein alpha (SIRPα) on their surface. Developed by SHIFTBIO, this platform leverages the high-affinity binding between SIRPα and CD47 to selectively target pathogenic cells that overexpress CD47, such as inflammatory macrophages and activated fibroblasts. In preclinical studies, SIRP-EV has been utilized both as a standalone agent for treating metabolic dysfunction-associated steatohepatitis (MASH)-associated liver fibrosis and as a delivery vehicle for antisense oligonucleotides (ASOs) targeting the NLRP3 inflammasome in models of inflammatory bowel disease (IBD). The dual-action approach combines the innate regenerative properties of MSC-derived EVs with precise targeting of the CD47-mediated "don't eat me" signaling axis and intracellular inflammasome inhibition.

Other names

SIRPα-engineered extracellular vesiclesMSC-derived SIRPα-engineered extracellular vesiclesSIRP-EV-NLRP3 ASOSIRP-EV-NLRP-3 ASOSIRP-EV-NLRP 3 ASO